enGene Holdings Inc. (NASDAQ:ENGN) Receives Average Rating of "Buy" from Analysts

enGene Holdings Inc. (NASDAQ:ENGN - Get Free Report) has earned an average rating of "Buy" from the eight analysts that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among analysts that have covered the stock in the last year is $23.29.

Several research firms have issued reports on ENGN. JMP Securities restated a "market outperform" rating and issued a $18.00 price objective on shares of enGene in a research note on Tuesday, April 29th. HC Wainwright reaffirmed a "buy" rating and set a $25.00 price target on shares of enGene in a research report on Tuesday, March 11th. Morgan Stanley decreased their price objective on enGene from $37.00 to $34.00 and set an "overweight" rating for the company in a report on Tuesday, March 11th. Piper Sandler initiated coverage on shares of enGene in a report on Tuesday, February 18th. They issued an "overweight" rating and a $26.00 target price on the stock. Finally, UBS Group cut shares of enGene from a "buy" rating to a "neutral" rating and decreased their price target for the stock from $34.00 to $7.00 in a research note on Friday, February 14th.

enGene Stock Down 3.8 %

Shares of NASDAQ ENGN traded down $0.13 during mid-day trading on Monday, reaching $3.26. The company had a trading volume of 6,280 shares, compared to its average volume of 126,416. The firm has a 50 day simple moving average of $4.45 and a two-hundred day simple moving average of $6.34. enGene has a 52-week low of $3.25 and a 52-week high of $14.67. The company has a current ratio of 16.87, a quick ratio of 16.87 and a debt-to-equity ratio of 0.08. The stock has a market cap of $166.19 million, a P/E ratio of -5.62 and a beta of -0.36.

Institutional Trading of enGene

Several hedge funds have recently made changes to their positions in ENGN. Vontobel Holding Ltd. purchased a new position in enGene during the fourth quarter worth about $69,000. Jane Street Group LLC purchased a new position in shares of enGene during the 4th quarter worth approximately $93,000. Toronto Dominion Bank acquired a new stake in shares of enGene in the 4th quarter valued at approximately $97,000. Cubist Systematic Strategies LLC boosted its stake in shares of enGene by 15.7% in the fourth quarter. Cubist Systematic Strategies LLC now owns 15,342 shares of the company's stock valued at $102,000 after buying an additional 2,080 shares in the last quarter. Finally, Corton Capital Inc. acquired a new position in enGene during the fourth quarter worth $157,000. Institutional investors and hedge funds own 64.16% of the company's stock.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.